UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): November 2, 2018
TABULA RASA HEALTHCARE, INC.
(Exact Name of Registrant Specified in Charter)
Delaware |
|
001-37888 |
|
46-5726437 |
228 Strawbridge Drive |
|
|
Moorestown, New Jersey |
|
08057 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrants telephone number, including area code: (866) 648-2767
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(d)
On November 2, 2018, the Board of Directors (the Board) of Tabula Rasa HealthCare, Inc. (the Company) appointed Kathrine OBrien as a director of the Company to fill an existing vacancy on the Board. Ms. OBrien will serve as a Class I director, to serve until the 2020 annual meeting of stockholders or until her earlier resignation, retirement or other termination of service. It is contemplated that Ms. OBrien may serve on certain committees of the Companys Board, but no such committee appointments have been made at this time. The Board has determined that Ms. OBrien is an independent director in accordance with applicable rules of the Securities and Exchange Commission (the SEC) and the Nasdaq Stock Market. Ms. OBrien will be compensated in accordance with the non-employee director compensation program of the Board, as described in the Companys Proxy Statement filed with the SEC on May 1, 2018.
Ms. OBrien, 56, has been a consultant since October 2018. Previously, she served as Vice President and General Manager for Skin and Marketing Services at Unilever, an international consumer goods company, from July 2014 to September 2018. Ms. OBrien served as Vice President, Marketing Services, for Unilever from May 2012 to June 2014 and has worked in various other roles for Unilever since 1984. Over the course of her career, Ms. OBrien has led marketing teams for personal care and foods, and she has served on the Lehigh Valley Hospital Network Board of Trustees and on the board of Cosmetic Executive Women. Ms. OBrien received a Master of Business Administration from Columbia University and holds a Bachelor of Arts in Economics from Boston College. The Board believes that Ms. OBriens extensive experience as a marketing executive will make her a valuable member of the Companys Board.
In connection with her appointment, Ms. OBrien will enter into the Companys standard indemnification agreement, the form of which was previously filed with the Companys Registration Statement on Form S-1 (Registration No. 333-208857) in connection with the Companys initial public offering completed in October 2016. There is no other material Company plan, contract or arrangement in which Ms. OBrien will participate in connection with her appointments. There are no arrangements or understandings between Ms. OBrien and any other person pursuant to which Ms. OBrien was selected as a director of the Company, and there is no family relationship between Ms. OBrien and any of the Companys other directors or executive officers. There are also no related party transactions between either of Ms. OBrien and the Company.
Item 7.01 Regulation FD Disclosure.
On November 5, 2018, the Company issued a press release announcing the appointment of Ms. OBrien to the Board. The Company is furnishing a copy of the press release, which is attached hereto as Exhibit 99.1.
The information provided in this Item 7.01 of this Current Report on Form 8-K is being furnished and shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that Section. The information in this Current Report shall not be deemed to be incorporated by reference in any filing made by the Company pursuant to the Securities Act of 1933, as amended, or the Exchange Act other than to the extent that such filing incorporates by reference any or all of such information by express reference thereto.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit Number |
|
Description |
|
|
|
99.1 |
|
Press release of Tabula Rasa HealthCare, Inc. issued November 5, 2018 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
TABULA RASA HEALTHCARE, INC. | |
|
|
|
|
By: |
/s/ Dr. Calvin H. Knowlton |
|
|
Dr. Calvin H. Knowlton |
|
|
Chief Executive Officer |
|
| |
Dated: November 5, 2018 |
|
Tabula Rasa HealthCare Appoints New Member to its Board of Directors
Senior CPG Marketing Executive Kathy OBrien Joins Board
Moorestown, NJ (November 5, 2018) - Tabula Rasa HealthCare, Inc. (NASDAQ: TRHC), a healthcare technology company advancing the field of medication safety, appointed Kathrine OBrien to its Board of Directors. The appointment occurred at TRHCs meeting of the Board of Directors held on November 2, 2018 and was effective immediately.
Ms. OBrien is a recognized consumer packaged goods (CPG) executive with 30 years of experience. Most recently she served as Vice President/General Manager for Skin and Marketing Services for Unilever Corporation headquartered in Englewood Cliffs, NJ. She had full P&L responsibility for a $1.5B business, leading a team of marketing professionals and controlling a multi-million annual marketing budget.
Ms. OBrien led Unilevers launch of the Dove Campaign for Real Beauty in the United States reaching more than five million young women with the campaigns unique self-esteem programming. She also is a forerunner in digital and social media marketing, leading the Dove brands first ever brand partnership with Twitter. The campaign was recognized with two Cannes Lions and AdWeeks Media Plan of the Year.
Kathy OBrien is a marketing innovator to which her successes attest, said TRHC Chairman and CEO Calvin H. Knowlton, PhD. She is a dynamic, inspirational leader that can effectively build strong and cohesive organizations and lead cross-functional teams. This skill set is exactly the kind of expertise a growing, expanding company like Tabula Rasa HealthCare should have to advise us at this juncture in our journey as we continue to grow. We enthusiastically welcome Ms. OBrien to TRHCs Board of Directors, and we believe she will be a valuable member of our Board.
Recognized for her prowess in business and marketing, Ms. OBrien received the 2015 Cosmetic Executive Woman Achiever of the Year award, the Top Women in Grocery 2012, Top 100 Irish Business People 2011 and Advertising Age Women to Watch 2010.
Ms. OBrien will serve as a Class I director until the 2020 annual meeting of stockholders or until her earlier resignation, retirement or other termination of service. Ms. OBriens appointment fills an existing vacancy on the Board. Ms. OBrien graduated from Columbia University with a Master of Business Administration and Boston College with a Bachelor of Arts in Economics.
About Tabula Rasa HealthCare®
Tabula Rasa HealthCare (TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize patient outcomes, lower healthcare costs and improve organizational performance. Medication risk management is TRHCs lead offering, and its cloud-based software applications provide solutions for a range of payers, providers and other healthcare organizations. For more information, visit TRHC.com. Follow us on Twitter @TabulaRasaHC for up-to-date information.
Contact:
Media
Dianne Semingson
dsemingson@TRHC.com
T: 215-870-0829
Investor
Bob East or Asher Dewhurst
Westwicke Partners
443-213-0500
tabularasa@westwicke.com